Sci-Tech Seattle: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Seattle.

Press releases published on May 4, 2026

May 4, 2026

Kentucky Blood Center: Now Live on Forcyte™ Scheduling Platform

Indeterminate EIN Presswire

May 4, 2026

Voast Debuts Refreshed Brand Identity, Formally Introducing the Interview Booth Category to the Events Industry

Indeterminate EIN Presswire

May 4, 2026

Starweaver to Host Global Summit with 20+ Global Speakers on AI in Professional Education on May 14, 2026

Indeterminate EIN Presswire

May 4, 2026

Axiant Launches with Innovative Process-First Methodology to Address Automation Failures

Indeterminate GlobeNewswire

May 4, 2026

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

Indeterminate GlobeNewswire

May 4, 2026

NANOBIOTIX ANNONCE UN AMENDEMENT DU PROTOCOLE DE L’ÉTUDE MONDIALE DE PHASE 3 SUR LE CANCER DE LA TÊTE ET DU COU

Indeterminate GlobeNewswire

May 4, 2026

Edgesource Corporation Acquires Lyteworx Automation Systems, Deepening Its Defense and Intelligence Mission Capabilities

Indeterminate GlobeNewswire

May 4, 2026

JIADE LIMITED Announces Pricing of up to $12.0 Million Registered Direct Offering

Indeterminate GlobeNewswire

May 4, 2026

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

Indeterminate GlobeNewswire

May 4, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

May 4, 2026

Teva to Present at the BofA Securities Health Care Conference

Indeterminate GlobeNewswire

May 4, 2026

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

May 4, 2026

Cellectis to Report First Quarter Financial Results on May 11, 2026

Indeterminate GlobeNewswire

May 4, 2026

Cellectis publiera ses résultats financiers du premier trimestre le 11 mai 2026

Indeterminate GlobeNewswire

May 4, 2026

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

Indeterminate GlobeNewswire

May 4, 2026

Microvast Schedules First Quarter Earnings Call

Indeterminate GlobeNewswire

May 4, 2026

Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program

Indeterminate GlobeNewswire

May 4, 2026

Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Indeterminate GlobeNewswire

May 4, 2026

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Indeterminate GlobeNewswire

May 4, 2026

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Indeterminate GlobeNewswire